Miguel HUESO

Dr. Miguel HUESO

Department of Nephrology, Hospital Universitari de Bellvitge
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2006 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
FMFrancesc Moreso
Francesc Moreso
MIM. Ibernon
M. Ibernon
MGM. Gomà
M. Gomà
MCM. Carrera
M. Carrera
XFX. Fulladosa
X. Fulladosa
DSD. Serón
D. Serón
Chronic allograft nephropathy (CAN) in protocol biopsies is associated with graft loss while the association between subclinical rejection (SCR) and outcome has yielded contradictory results. We analyze the predictive value of SCR and/or CAN in protocol biopsies on death-censored graft survival. Since 1988, a protocol biopsy was done during the first 6 months in stable grafts with serum creatinine <300 μmol/L and proteinuria <1 g/day. Biopsies were evaluated according to Banff criteria. Borderline changes and acute rejection were grouped as SCR. CAN was defined as presence of interstitial fibrosis and tubular atrophy. Mean follow-up was 91 ± 46 months. Sufficient tissue was obtained in 435 transplants. Biopsies were classified as normal (n = 186), SCR (n = 74), CAN (n = 110) and SCR with CAN (n = 65). Presence of SCR with CAN was associated with old donors, percentage of panel reactive antibodies and presence of acute rejection before protocol biopsy. Cox regression analysis showed that SCR with CAN (relative risk [RR]: 1.86, 95% confidence interval [CI]: 1.11–3.12; p = 0.02) and hepatitis C virus (RR: 2.27, 95% CI: 1.38–3.75; p = 0.01) were independent predictors of graft survival. In protocol biopsies, the detrimental effect of interstitial fibrosis/tubular atrophy on long-term graft survival is modulated by SCR.

1 February 2002 in Kidney International
Verified
Journal Article
Closed access
DSDaniel Serón
Daniel Serón
FMFrancesc Moreso
Francesc Moreso
XFXavier Fulladosa
Xavier Fulladosa
Miguel HUESOMiguel HUESO
Miguel HUESO
MCMarta Carrera
Marta Carrera
JGJosep M. Grinyó
Josep M. Grinyó

15 January 2012 in Transplantation
Verified
Journal Article
Closed access
FMFrancesc Moreso
Francesc Moreso
MCMarta Carrera
Marta Carrera
MGMontse Goma
Montse Goma
Miguel HUESOMiguel HUESO
Miguel HUESO
JSJoana Sellares
Joana Sellares
DSDaniel Serón
Daniel Serón
Background. Subclinical rejection and interstitial fibrosis and tubular atrophy (IF/TA) in protocol biopsies are associated with outcome. We study the relationship between histologic lesions in early protocol biopsies and histologic diagnoses in late biopsies for cause. Materials and Methods. Renal transplants with a protocol biopsy performed within the first 6 months posttransplant between 1988 and 2006 were reviewed. Biopsies were evaluated according to Banff criteria, and C4d staining was available in biopsies for cause. Results. Of the 517 renal transplants with a protocol biopsy, 109 had a subsequent biopsy for cause which showed the following histological diagnoses: chronic humoral rejection (CHR) (n=44), IF/TA (n=42), recurrence of the primary disease (n=11), de novo glomerulonephritis (n=7), T-cell-mediated rejection (n=4), and polyoma virus nephropathy (n=1). The proportion of retransplants (15.9% vs. 2.3%, P=0.058) and the prevalence of subclinical rejection were higher in patients with CHR than in patients with IF/TA (52.3% vs. 28.6%, P=0.0253). Demographic donor and recipient characteristics and clinical data at the time of protocol biopsy were not different between groups. Logistic regression analysis showed that subclinical rejection (relative risk, 2.52; 95% confidence interval, 1.1–6.3; P=0.047) but not retransplantation (relative risk, 6.7; 95% confidence interval, 0.8–58.8; P=0.085) was associated with CHR. Conclusion. Subclinical rejection in early protocol biopsies is associated with late appearance of CHR.

1 May 2000 in Transplantation
Verified
Journal Article
Closed access
DSD Serón
D Serón
FMFrancesc Moreso
Francesc Moreso
JRJ M Ramón
J M Ramón
Miguel HUESOMiguel HUESO
Miguel HUESO
ECE Condom
E Condom
JGJ M Grinyó
J M Grinyó
The minimum sample size to perform a clinical trial aimed to modify the natural history of chronic allograft nephropathy (CAN) is very large. Since the presence of chronic tubulointerstitial damage in renal protocol biopsy specimens is an independent predictor of late outcome, we evaluated whether protocol biopsies could facilitate the design of trials aimed to prevent or treat CAN. Two hundred eighty-two protocol biopsy specimens were obtained 3 months after transplantation in 280 patients with serum creatinine levels <300 micromol/L, proteinuria <1000 mg/day, and stable function. The specimens were evaluated according to the Banff criteria. Graft survival depended on the presence of CAN and renal transplant vasculopathy (RTV). Thus, biopsy specimens were classified as: (a) no CAN (n=174); (b) CAN without RTV (n=87); and (c) CAN with RTV (n=21). Graft survival at 10 years was 95%, 82%, and 41%, respectively (P=0.001). Total serum cholesterol before transplantation was 4.5+/-1.1, 4.6+/-1.1, and 5.3+/-1.6 mmol/L, respectively (P=0.009) and it was the only predictor of RTV. Power analysis (beta=20%, alpha=5%) was done to evaluate whether protocol biopsies can facilitate the design of clinical trials aimed either to prevent or treat CAN. We showed that the most feasible approach would be to use the presence of CAN as the primary efficacy end point in a prevention trial. To demonstrate a 50% reduction in the incidence of CAN at 3 months, 570 patients would be required. Protocol biopsies may allow a reduction of sample size and especially the time of follow-up in a trial aimed to prevent CAN.

27 December 1998 in Transplantation
Verified
Journal Article
Closed access
Miguel HUESOMiguel HUESO
Miguel HUESO
JBJordi Bover
Jordi Bover
DSDaniel Serón
Daniel Serón
SGSalvador Gil-Vernet
Salvador Gil-Vernet
ISIsabel Sabaté
Isabel Sabaté
JGJosep M. Grinyó
Josep M. Grinyó
Background. Cyclosporine (CsA) nephrotoxicity can be identified by functional changes and chronic renal damage. CsA-associated renal fibrosis has been related to the overproduction of transforming growth factor (TGF)-β1, a fibrogenic cytokine. Mycophenolate mofetil (MMF) may allow CsA dose reduction without increasing the risk of rejection. Methods. We studied the impact of CsA dose reduction in association with MMF on renal function and TGF-β1 production in 16 long-term renal allograft recipients with suspected CsA nephrotoxicity. Two grams/day of MMF were introduced, and CsA dose was reduced to reach whole-blood levels between 40 and 60 ng/ml within 1 month. CsA dose and levels, renal function parameters, and platelet-poor plasma TGF-β1 levels were evaluated before and 6 months thereafter. Results. MMF allowed a decrease in both the mean dose of CsA (3.8±1.35 vs. 2.2±0.73 mg/kg/day; P<0.01) and CsA levels (148±36 vs. 53±19 ng/ml; P<0.001). The reduction of CsA was associated with a decrement of serum creatinine levels (210±46 vs. 172±41 µmol/L; P<0.001) and an increase in both the glomerular filtration rate (32.9±12 vs. 39.1±14 ml/min/1.73 m2; P<0.02) and renal plasma flow (195±79 to 218.6±74.02 ml/min/1.73 m2; P<0.02). There was a reduction in plasma TGF-β1 levels (4.6±4.2 vs. 2.0±1.4 ng/ml; P=0.003) and CsA levels correlated with TGF-β1 (r=0.536, P=0.002). No rejection episodes occurred and an improvement in both systolic (149±13 vs. 137±12 mmHg; P<0.01) and diastolic blood pressure (89±14 vs. 83±10 mmHg; P<0.04) were observed. Conclusions. These short-term results show that MMF introduction allows a CsA dose reduction, which improves renal function, reduces TGF-β1 production, and improves the control of hypertension, without increasing the incidence of acute rejection.

Verified
Journal Article
Open access
PDF file
Miguel HUESOMiguel HUESO
Miguel HUESO
ABAdrián Bareas
Adrián Bareas
MSMarc Suñé-Pou
Marc Suñé-Pou
JAJosep M. Aran
Josep M. Aran
Josep Suñé-NegreJosep Suñé-Negre
Josep Suñé-Negre
Estanis NavarroEstanis Navarro
Estanis Navarro
Non-coding RNAs (ncRNAs) are emerging therapeutic tools but there are barriers to their translation to clinical practice. Key issues concern the specificity of the targets, the delivery of the molecules, and their stability, while avoiding “on-target” and “off-target” side effects. In this “ncRNA in therapeutics” issue, we collect several studies of the differential expression of ncRNAs in cardiovascular diseases, bone metabolism-related disorders, neurology, and oncology, and their potential to be used as biomarkers or therapeutic targets. Moreover, we review recent advances in the use of antisense ncRNAs in targeted therapies with a particular emphasis on their basic biological mechanisms, their translational potential, and future trends.